| Date | Title | Description | Source |
| 27.03.2024 | Recbio And Rongsheng Biotech Signed a Strategic Cooperation ... | TAIZHOU, China, March 27, 2024 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (hereafter referr... | en.prnasia... |
| 21.03.2024 | Jiangsu Recbio Technology Co., Ltd. announced 2023 annual re... | TAIZHOU, China, March 21, 2024 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announce... | en.prnasia... |
| 29.12.2023 | Positive Results In The Interim Analysis Of The Clinical Tri... | TAIZHOU, China, Dec. 29, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company... | en.prnasia... |
| 24.10.2023 | Recbio appeared at the 14th China (Taizhou) International Ph... | TAIZHOU, China, Oct. 24, 2023 /PRNewswire/ -- From October 19 to 22, the 14th China (Taizhou) Intern... | en.prnasia... |
| 10.10.2023 | Recbio signed a strategic cooperation agreement with Zimbabw... | TAIZHOU, China, Oct. 10, 2023 /PRNewswire/ -- On October 8, 2023, Dr. Deckster Tonny SAVADYE, CEO of... | en.prnasia... |
| 28.08.2023 | Jiangsu Recbio Technology Co., Ltd. announced 2023 interim r... | TAIZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced... | en.prnasia... |
| 27.07.2023 | Acceptance Of Clinical Trial Application For The Recbio's No... | TAIZHOU, China, July 27, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Board&qu... | en.prnasia... |
| 17.05.2023 | Inclusion of Recbio In the MSCI China Small Cap Index | TAIZHOU, China, May 17, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company&... | en.prnasia... |
| 21.03.2023 | Two-Component Recombinant COVID-19 Vaccine ReCOV Granted Wit... | TAIZHOU, China, March 21, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Compan... | en.prnasia... |
| 13.02.2023 | Completion Of The First Batch Of Subject Enrollment For The ... | TAIZHOU, China, Feb. 13, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company... | en.prnasia... |
| 26.12.2022 | Superior Neutralizing Antibody Titer Levels Against Omicron ... | TAIZHOU, China, Dec. 25, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company... | einpresswi... |
| 26.12.2022 | Superior Neutralizing Antibody Titer Levels Against Omicron ... | TAIZHOU, China, Dec. 26, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company... | en.prnasia... |
| 19.12.2022 | Clinical Trial Approval For The Company's Novel Adjuvanted R... | TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company... | einpresswi... |
| 19.12.2022 | Clinical Trial Approval For The Company's Novel Adjuvanted R... | TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company... | en.prnasia... |
| 14.12.2022 | Superior Results Of The Comparative Study Of The Company's R... | TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company... | en.prnasia... |
| 21.11.2022 | Jiangsu Recbio Technology Co., Ltd. Increases Production For... | TAIZHOU, China, Nov. 21, 2022 /PRNewswire/ -- (the "Company", together with its subsidiari... | en.prnasia... |
| 21.11.2022 | Jiangsu Recbio Technology Co., Ltd. Increases Production For... | TAIZHOU, China, Nov. 21, 2022 /PRNewswire/ -- (the "Company", together with its subsidiari... | einpresswi... |
| 08.11.2022 | Update on overseas clinical trials progress of novel adjuvan... | TAIZHOU, China, Nov. 8, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company&... | en.prnasia... |
| 28.10.2022 | Acceptance Of The Application For Clinical Trial Of Recbio N... | TAIZHOU, China, Oct. 28, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company... | en.prnasia... |
| 29.08.2022 | Recbio Announces Interim results for the Fiscal Year 2022 an... | The nine-valent HPV vaccine and other blockbuster varieties have been advanced efficiently.
Cash res... | en.prnasia... |
| 19.08.2022 | Completion Of Subject Enrollment And Vaccination For The Com... | TAIZHOU, China, Aug. 18, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company... | einpresswi... |
| 19.08.2022 | Completion Of Subject Enrollment And Vaccination For The Com... | TAIZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company... | en.prnasia... |
| 10.08.2022 | Recbio announces Phase III Clinical Trial Progress Of Recomb... | TAIZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company&... | en.prnasia... |
| 03.08.2022 | Approval Of The Comparative Study Between ReCOV And mRNA Vac... | TAIZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company&q... | en.prnasia... |
| 27.06.2022 | Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicro... | TAIZHOU, China, June 27, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. is pleased to anno... | en.prnasia... |
| 05.05.2022 | Clinical Trial Approval For ReCOV In The PRC And The Oversea... | TAIZHOU, China, May 5, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company&qu... | en.prnasia... |
| 13.04.2022 | Receipt Of Approval From The UAE For Phase II/III Clinical T... | TAIZHOU, China, April 13, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company... | en.prnasia... |
| 11.04.2022 | Successful Passing Of The EU Qualified Person Audit Of The G... | TAIZHOU, China, April 11, 2022 /PRNewswire/ -- The board of directors of Jiangsu Recbio Technology C... | en.prnasia... |
| 21.03.2022 | Recbio Announces Proposed Listing on the Main Board of the H... | Offer Price of HK $24.80 per H Share
To Raise Proceeds Up to HK$765 Million
Focus on the R&D of ... | en.prnasia... |
| 15.02.2022 | Recbio Provides Updates on First Lyophilized mRNA Vaccine an... | TAIZHOU, China, Feb. 15, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (Recbio), a China-... | en.prnasia... |
| 17.01.2022 | The Philippines Has Approved ReCOV For Phase II/III Cinical ... | Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clini... | en.prnasia... |
| 17.11.2021 | Recbio Receives Pharmaceutical Production License from Jiang... | TAIZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"... | en.prnasia... |
| 12.11.2021 | Recbio Announces Promising Preliminary Results From First-in... | Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abnormal... | en.prnasia... |
| 09.11.2021 | Recbio Announces New Study Showing Its COVID-19 Vaccine Indu... | TAIZHOU, China, Nov. 9, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"... | en.prnasia... |
| 29.09.2021 | Recbio and Rhegen Signed an mRNA Vaccine Cooperation Agreeme... | TAIZHOU, China, Sept. 29, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (referred to as &... | en.prnasia... |
